or Try an Advanced Search...

    Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 6.94 -3.61% -0.26
    BDTX closed down 3.61 percent on Wednesday, May 8, 2024, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical BDTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Earnings Movers Other 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Walk Strength -3.61%
    Earnings Movers Other -3.61%
    Inside Day Range Contraction -3.61%
    Wide Bands Range Expansion -3.61%
    Above Upper BB Strength -3.61%
    Older End-of-Day Signals for BDTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 16 hours ago
    Down 3% about 18 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    Down 2 % about 19 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BDTX Chart by TradingView
    Basic chart:

    Profile

    Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment Enzymes Diamond Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Genetic Diseases Oncogenes Therapies For Cancer Protein Kinase Rare Genetic Disease Rare Genetic Diseases Black Diamond Kinase

    Is BDTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 15 Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
    Apr 11 Black Diamond Therapeutics Announces Changes to Board of Directors
    Apr 8 Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
    Apr 7 Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
    Apr 3 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    Mar 22 How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
    Mar 14 Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...
    Mar 12 Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Mar 5 Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
    See more BDTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.66
    52 Week Low 1.57
    Average Volume 609,778
    200-Day Moving Average 3.56
    50-Day Moving Average 5.20
    20-Day Moving Average 5.81
    10-Day Moving Average 6.34
    Average True Range 0.51
    RSI (14) 65.87
    ADX 40.46
    +DI 39.14
    -DI 10.27
    Chandelier Exit (Long, 3 ATRs) 6.12
    Chandelier Exit (Short, 3 ATRs) 6.35
    Upper Bollinger Bands 7.33
    Lower Bollinger Band 4.29
    Percent B (%b) 0.87
    BandWidth 52.26
    MACD Line 0.53
    MACD Signal Line 0.36
    MACD Histogram 0.1679
    Fundamentals Value
    Market Cap 358.35 Million
    Num Shares 51.6 Million
    EPS -2.13
    Price-to-Earnings (P/E) Ratio -3.26
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.55
    Resistance 3 (R3) 7.60 7.45 7.45
    Resistance 2 (R2) 7.45 7.29 7.42 7.41
    Resistance 1 (R1) 7.19 7.20 7.12 7.14 7.38
    Pivot Point 7.04 7.04 7.00 7.02 7.04
    Support 1 (S1) 6.79 6.89 6.71 6.74 6.50
    Support 2 (S2) 6.64 6.79 6.61 6.47
    Support 3 (S3) 6.38 6.64 6.43
    Support 4 (S4) 6.33